Indolent B-cell non-Hodgkin lymphoma (INHL)

Clinical trials for Indolent B-cell non-Hodgkin lymphoma (INHL) explained in plain language.

Never miss a new study

Get alerted when new Indolent B-cell non-Hodgkin lymphoma (INHL) trials appear

Sign up with your email to follow new studies for Indolent B-cell non-Hodgkin lymphoma (INHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New antibody drug shows promise for Hard-to-Treat lymphoma

Disease control Ongoing

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

Matched conditions: INDOLENT B-CELL NON-HODGKIN LYMPHOMA (INHL)

Phase 1/2 • Sponsor: Genmab • Aim: Disease control

Last updated Sep 11, 2026 00:00 UTC

Indolent B-cell non-Hodgkin lymphoma (INHL)

Get alerted when new Indolent B-cell non-Hodgkin lymphoma (INHL) trials appear

New antibody drug shows promise for Hard-to-Treat lymphoma